Az antraciklinek kardiotoxikus hatásának kivédé se gyermekekben

Translated title of the contribution: Subacute cardiotoxicity caused by anthracycline therapy in children: Can dexrazoxane prevent this effect?

Hajna Erlaky, Kornélia Tóth, Judit Szabolcs, Erzsébet Horváth, Viktória Kemény, J. Müller, Mónika Csóka, László Jókúti, Dániel Erdélyi, Gábor Kovács

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives: The use of anthracyclines are limited by their cardiotoxic side effects (first of all congestive cardiomyopathy). In this study we analyzed the anthracycline-induced cardiotoxicity and the possible preventive role of dexrazoxane in children. Patients: 158 anthracycline-treated long-term survivors could be analyzed. Sixty-one children received dexrazoxane (group D) and 97 patients received anthracyclines only (group C). Methods: Cardiac ultrasound examinations (ECHO) and electrocardiograms (ECG) were performed regularly from the beginning of chemotherapy and yearly thereafter. Shortening fraction (FS) was used as indicator of the ventricular function. Results: The incidence of reduced left ventricular function (FS) was 13.4% in C, and 8.2% in D (p=ns). Two years after completion of the chemotherapy FS was reduced in 13.7% in C and 0% in D, respectively (p=0.056), and 5 years after therapy in 11.0% in C and 2.4% in D, respectively (P=0.034). Left chamber wall diameter was abnormal in systole in 6% in C and 2% in D, in diastole in 11% in C and 7% in D (p=ns) after 3 years of follow-up. Conclusion: Anthracycline-induced subacute cardiotoxicity can be significantly diminished by the concomitant use of dexrazoxane. For the final conclusions longer follow-up is necessary.

Original languageHungarian
Pages (from-to)25-32
Number of pages8
JournalMagyar Onkologia
Volume50
Issue number1
Publication statusPublished - 2006

Fingerprint

Dexrazoxane
Anthracyclines
Therapeutics
Drug Therapy
Diastole
Ventricular Function
Systole
Dilated Cardiomyopathy
Left Ventricular Function
Survivors
Electrocardiography
Cardiotoxicity
Incidence

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Erlaky, H., Tóth, K., Szabolcs, J., Horváth, E., Kemény, V., Müller, J., ... Kovács, G. (2006). Az antraciklinek kardiotoxikus hatásának kivédé se gyermekekben. Magyar Onkologia, 50(1), 25-32.

Az antraciklinek kardiotoxikus hatásának kivédé se gyermekekben. / Erlaky, Hajna; Tóth, Kornélia; Szabolcs, Judit; Horváth, Erzsébet; Kemény, Viktória; Müller, J.; Csóka, Mónika; Jókúti, László; Erdélyi, Dániel; Kovács, Gábor.

In: Magyar Onkologia, Vol. 50, No. 1, 2006, p. 25-32.

Research output: Contribution to journalArticle

Erlaky, H, Tóth, K, Szabolcs, J, Horváth, E, Kemény, V, Müller, J, Csóka, M, Jókúti, L, Erdélyi, D & Kovács, G 2006, 'Az antraciklinek kardiotoxikus hatásának kivédé se gyermekekben', Magyar Onkologia, vol. 50, no. 1, pp. 25-32.
Erlaky H, Tóth K, Szabolcs J, Horváth E, Kemény V, Müller J et al. Az antraciklinek kardiotoxikus hatásának kivédé se gyermekekben. Magyar Onkologia. 2006;50(1):25-32.
Erlaky, Hajna ; Tóth, Kornélia ; Szabolcs, Judit ; Horváth, Erzsébet ; Kemény, Viktória ; Müller, J. ; Csóka, Mónika ; Jókúti, László ; Erdélyi, Dániel ; Kovács, Gábor. / Az antraciklinek kardiotoxikus hatásának kivédé se gyermekekben. In: Magyar Onkologia. 2006 ; Vol. 50, No. 1. pp. 25-32.
@article{85ec2ed6bfc842c792e91cae501dfba6,
title = "Az antraciklinek kardiotoxikus hat{\'a}s{\'a}nak kiv{\'e}d{\'e} se gyermekekben",
abstract = "Objectives: The use of anthracyclines are limited by their cardiotoxic side effects (first of all congestive cardiomyopathy). In this study we analyzed the anthracycline-induced cardiotoxicity and the possible preventive role of dexrazoxane in children. Patients: 158 anthracycline-treated long-term survivors could be analyzed. Sixty-one children received dexrazoxane (group D) and 97 patients received anthracyclines only (group C). Methods: Cardiac ultrasound examinations (ECHO) and electrocardiograms (ECG) were performed regularly from the beginning of chemotherapy and yearly thereafter. Shortening fraction (FS) was used as indicator of the ventricular function. Results: The incidence of reduced left ventricular function (FS) was 13.4{\%} in C, and 8.2{\%} in D (p=ns). Two years after completion of the chemotherapy FS was reduced in 13.7{\%} in C and 0{\%} in D, respectively (p=0.056), and 5 years after therapy in 11.0{\%} in C and 2.4{\%} in D, respectively (P=0.034). Left chamber wall diameter was abnormal in systole in 6{\%} in C and 2{\%} in D, in diastole in 11{\%} in C and 7{\%} in D (p=ns) after 3 years of follow-up. Conclusion: Anthracycline-induced subacute cardiotoxicity can be significantly diminished by the concomitant use of dexrazoxane. For the final conclusions longer follow-up is necessary.",
author = "Hajna Erlaky and Korn{\'e}lia T{\'o}th and Judit Szabolcs and Erzs{\'e}bet Horv{\'a}th and Vikt{\'o}ria Kem{\'e}ny and J. M{\"u}ller and M{\'o}nika Cs{\'o}ka and L{\'a}szl{\'o} J{\'o}k{\'u}ti and D{\'a}niel Erd{\'e}lyi and G{\'a}bor Kov{\'a}cs",
year = "2006",
language = "Hungarian",
volume = "50",
pages = "25--32",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "1",

}

TY - JOUR

T1 - Az antraciklinek kardiotoxikus hatásának kivédé se gyermekekben

AU - Erlaky, Hajna

AU - Tóth, Kornélia

AU - Szabolcs, Judit

AU - Horváth, Erzsébet

AU - Kemény, Viktória

AU - Müller, J.

AU - Csóka, Mónika

AU - Jókúti, László

AU - Erdélyi, Dániel

AU - Kovács, Gábor

PY - 2006

Y1 - 2006

N2 - Objectives: The use of anthracyclines are limited by their cardiotoxic side effects (first of all congestive cardiomyopathy). In this study we analyzed the anthracycline-induced cardiotoxicity and the possible preventive role of dexrazoxane in children. Patients: 158 anthracycline-treated long-term survivors could be analyzed. Sixty-one children received dexrazoxane (group D) and 97 patients received anthracyclines only (group C). Methods: Cardiac ultrasound examinations (ECHO) and electrocardiograms (ECG) were performed regularly from the beginning of chemotherapy and yearly thereafter. Shortening fraction (FS) was used as indicator of the ventricular function. Results: The incidence of reduced left ventricular function (FS) was 13.4% in C, and 8.2% in D (p=ns). Two years after completion of the chemotherapy FS was reduced in 13.7% in C and 0% in D, respectively (p=0.056), and 5 years after therapy in 11.0% in C and 2.4% in D, respectively (P=0.034). Left chamber wall diameter was abnormal in systole in 6% in C and 2% in D, in diastole in 11% in C and 7% in D (p=ns) after 3 years of follow-up. Conclusion: Anthracycline-induced subacute cardiotoxicity can be significantly diminished by the concomitant use of dexrazoxane. For the final conclusions longer follow-up is necessary.

AB - Objectives: The use of anthracyclines are limited by their cardiotoxic side effects (first of all congestive cardiomyopathy). In this study we analyzed the anthracycline-induced cardiotoxicity and the possible preventive role of dexrazoxane in children. Patients: 158 anthracycline-treated long-term survivors could be analyzed. Sixty-one children received dexrazoxane (group D) and 97 patients received anthracyclines only (group C). Methods: Cardiac ultrasound examinations (ECHO) and electrocardiograms (ECG) were performed regularly from the beginning of chemotherapy and yearly thereafter. Shortening fraction (FS) was used as indicator of the ventricular function. Results: The incidence of reduced left ventricular function (FS) was 13.4% in C, and 8.2% in D (p=ns). Two years after completion of the chemotherapy FS was reduced in 13.7% in C and 0% in D, respectively (p=0.056), and 5 years after therapy in 11.0% in C and 2.4% in D, respectively (P=0.034). Left chamber wall diameter was abnormal in systole in 6% in C and 2% in D, in diastole in 11% in C and 7% in D (p=ns) after 3 years of follow-up. Conclusion: Anthracycline-induced subacute cardiotoxicity can be significantly diminished by the concomitant use of dexrazoxane. For the final conclusions longer follow-up is necessary.

UR - http://www.scopus.com/inward/record.url?scp=33747438927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747438927&partnerID=8YFLogxK

M3 - Article

VL - 50

SP - 25

EP - 32

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 1

ER -